• Publications
  • Influence
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
Purpose: To characterize the population pharmacokinetics of trastuzumab in patients with metastatic breast cancer. Methods: A nonlinear mixed effect model was based on pharmacokinetic data from phaseExpand
  • 215
  • 17
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
PURPOSE The population pharmacokinetic/pharmacodynamic (PK/PD) approach was prospectively integrated in the clinical development of docetaxel to assess the PK profile in a large population ofExpand
  • 400
  • 14
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.
PURPOSE We developed a drug-disease simulation model to predict antitumor response and overall survival in phase III studies from longitudinal tumor size data in phase II trials. METHODS WeExpand
  • 178
  • 13
A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation
A sparse sampling strategy (3 samples per patient, 521 patients) was implemented in 22 Phase 2 studies of docetaxel (Taxotere®) at the first treatment cycle for a prospective populationExpand
  • 189
  • 13
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
ObjectiveTo characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy agents on it’s pharmacokineticExpand
  • 272
  • 11
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Docetaxel is a chemotherapeutic agent effective in the treatment of various solid tumors. Patients given a standard dose of docetaxel exhibit wide interpatient variation in clearance (CL) and toxicExpand
  • 184
  • 11
  • PDF
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
Our objective was to assess the pharmacokinetics of erlotinib in a large patient population with solid tumors, identify covariates, and explore relationships between exposure and safety outcomesExpand
  • 198
  • 10
Population Pharmacokinetics of Rituximab (Anti‐CD20 Monoclonal Antibody) in Rheumatoid Arthritis Patients During a Phase II Clinical Trial
Rituximab is a B cell‐depleting anti‐CD20 chimeric IgGK monoclonal antibody being investigated for the treatment of rheumatoid arthritis. The purpose of this study was to develop a populationExpand
  • 164
  • 10
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Taxotere (N-debenzoyl-N-tert-butoxycarbonyl-10-deacetyl Taxol; RP 56976; NSC 628503) is a semisynthetic analogue of Taxol. It is twice as active in inhibiting tubuline depolymerization and has aExpand
  • 241
  • 6
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma
Atezolizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death‐ligand 1 (PD‐L1), is US Food and Drug Administration (FDA) approved in metastatic urothelialExpand
  • 63
  • 6